XM does not provide services to residents of the United States of America.
G
G

GSK

News

Gsk PLC Says Single Dose Of Arexvy Shows Robust Immune Response In Adults 18-49

BRIEF-Gsk PLC Says Single Dose Of Arexvy Shows Robust Immune Response In Adults 18-49 Oct 24 (Reuters) - GSK plc GSK.L : GSK PLC - NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK GSK PLC - SINGLE DOSE OF AREXVY SHOWS ROBUST IMMUNE RESPONSE IN ADULTS 18-49 GSK PLC - TWO DOSES OF AREXVY IN IMMUNOCOMPROMISED ADULTS SHOW SIMILAR RESPONSE TO ONE DOSE
G

Shell setback upsets Nigeria's quest to lure investment

ANALYSIS-Shell setback upsets Nigeria's quest to lure investment Exxon Mobil decision was approved but after long wait Shell has not commented and regulator has not explained Some investors see positive change By MacDonald Dzirutwe LAGOS, Oct 23 (Reuters) - Nigeria's decision this week to block Shell's SHEL.L $2.4 billion sale of its onshore assets has sent a negative signal to investors the country urgently needs to strengthen its all-important oil sector, analysts said.
B
G

Northwestern sues Moderna for patent infringement over 19 vaccines

Northwestern sues Moderna for patent infringement over COVID-19 vaccines By Blake Brittain Oct 16 (Reuters) - Moderna MRNA.O was hit with a new patent lawsuit on Wednesday in Delaware federal court from Northwestern University, which accused the company of misusing the school's innovations to develop its blockbuster COVID-19 vaccine Spikevax. The lawsuit said Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport fragile messenger
G
P

UK Stocks-Factors to watch on Oct. 16

UPDATE 1-UK Stocks-Factors to watch on Oct. 16 Adds news items Oct 16 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening h igher on Wednesday, with futures FFIc1 u p 0 .4%. * ANTOFAGASTA: Antofagasta ANTO.L reported a 15% rise in third-quarter copper output compared to the second quarter, due to destocking of inventories at its Los Pelambres mine and better grades at its Centinela mine in Chile.
A
G
W

UK Stocks-Factors to watch on Oct 16

UK Stocks-Factors to watch on Oct 16 Oct 16 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening lower on Wednesday, with futures FFIc1 down 0.09%. * GSK: British drugmaker GlaxoSmithKline GSK.L sued Moderna MRNA.O in U.S. federal court in Delaware on Tuesday, accusing it of violating GSK patent rights in messenger RNA technology with its blockbuster COVID-19 vaccine Spikevax and RSV shot mResvia.
B
G
W
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.